Chronic pain caused by the nerve damage of type 2 diabetes, surgical amputation, chemotherapy and other conditions is especially intractable because it resists painkilling medications.
But in a study on mice, a Duke University team has shown that injections of stem cells from bone marrow might be able to relieve this type of neuropathic pain. The researchers say their findings, which appear July 13 in the Journal of Clinical Investigation, may also advance cell-based therapies in chronic pain conditions, lower back pain and spinal cord injuries.
The team used a type of stem cell known as bone marrow stromal cells (BMSCs), which are known to produce an array of healing factors and can be coaxed into forming most other types of cells in the body.
Stromal cells are already being tested in small-scale clinical studies of people with inflammatory bowel disease, heart damage and stroke. They have also shown promise for treating pain. However, it’s not clear how they work.
“Based on these new results, we have the know-how and we can further engineer and improve the cells to maximize their beneficial effects,” said Ru-Rong Ji, professor of anesthesiology and neurobiology in the Duke School of Medicine.
In his team’s study, the researchers used stromal cells to treat mice with pain caused by nerve damage. They delivered the cells by a lumbar puncture, infusing them into the fluid that bathes the spinal cord.
Mice treated with the bone marrow stromal cells were much less sensitive to painful stimuli after their nerve injury compared with the untreated mice, the researchers found.
“This analgesic effect was amazing,” Ji said. “Normally, if you give an analgesic, you see pain relief for a few hours, at most a few days. But with bone marrow stem cells, after a single injection we saw pain relief over four to five weeks.”
Pictures of the animals’ spinal cords showed that the injected stem cells had set up shop alongside the nerve cells in the spinal cord.
To understand how the stem cells alleviated pain, the researchers measured levels of anti-inflammatory molecules that had been previously linked to pain, finding that one in particular, TGF-?1, was present in higher amounts in the spinal fluid of the stem cell-treated animals compared with the untreated animals.
TGF-?1 is a protein that is typically secreted by immune cells and is common throughout the body. Research has shown that people with chronic pain have too little TGF-?1, Ji said.
In the new study, chemically neutralizing TGF-?1 reversed the pain-killing benefit of the BMSCs, suggesting that the secretion of this protein was a major reason why the cells helped with pain. Injecting TGF-?1 directly into spinal cord fluid provides relief too, but only for a few hours, Ji said.
By contrast, bone marrow stromal cells stay on site for as much as three months after the infusion, the scientists found. This is the right length of time, Ji said, because if the stem cells stayed permanently there could be risk of them becoming cancerous.
Importantly, BMSCs also migrate to the site of injury. That’s because a molecule emitted from the injured nerve cells called CXCL12 — which has also previously been linked to neuropathic pain — acts as a homing signal of sorts, attracting the stem cells.
The Latest on: Neuropathic pain
via Google News
The Latest on: Neuropathic pain
- Neuropathy Pain Treatment Market Unidentified Segments - The Biggest Opportunity Of 2020on March 21, 2020 at 7:22 am
The latest release from HTF MI highlights the key market trends impacting the growth of the Global Neuropathy Pain Treatment market. The study highlights influencing factors that are impacting or ...
- A Thermal Place Preference Test for Discovery of Neuropathic Pain Drugs.on March 20, 2020 at 10:15 am
Developing potent non-opioid pain medications is an integral part of the battle to conquer both chronic pain and the current opioid crisis. Although most screening approaches use in vitro surrogate ...
- New clinic offers ketamine infusions and pain managementon March 20, 2020 at 8:46 am
In the last decade, research has shown lower-than-anesthetic doses of ketamine can be safely and effectively used in an outpatient clinic for treating depression, painful conditions either acute or ...
- Appropriate referral and selection of patients with chronic pain for Spinal Cord Stimulation: European consensus recommendations and e-health tool.on March 19, 2020 at 7:00 am
Spinal cord stimulation (SCS) is an established treatment for chronic neuropathic, neuropathic-like and ischaemic pain. However, the heterogeneity of patients in daily clinical practice makes it often ...
- Surgery Cuts Chronic Sciatica Pain vs Conservative Treatmenton March 18, 2020 at 2:41 pm
Superficial wound infection and postoperative, new-onset neuropathic pain were the most common adverse events in patients who had surgery. One patient in the surgery group experienced recurrent disk ...
- Pain Management Therapeutics Market will Likely Rise to US$ 92,123.4 Million by the End of 2027on March 16, 2020 at 9:10 am
Non-narcotic analgesics are the drugs which act on peripheral nerve endings, although their antipyretic effect is mediated centrally. Cancer Pain Management Therapeutics to be Highly Lucrative Segment ...
- What Is Radiating Pain and What Can Cause It?on March 15, 2020 at 5:00 pm
It begins in one place then spreads across a bigger area. For example, if you have a herniated disc, you may have pain in your lower back. This pain might travel along the sciatic nerve, which runs ...
- Pain Therapeutics Market Forecasts to 2028 - Advances in Pharmacogenomics & Pharmacogenetics Enabling the Development of Personalized Managementon March 13, 2020 at 3:45 am
/PRNewswire/ -- The "Pain Therapeutics - Drugs, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
- Sciatica and MS: Are They Connected?on March 5, 2020 at 3:38 pm
Sciatica is a specific kind of pain caused by pinching or damage to the sciatic nerve. This nerve extends from the lower back, through the hips and buttocks, and splits down both legs. The pain ...
- Neuropathic Pain Management Market: Study Navigating the Future Growth Outlookon February 28, 2020 at 1:34 am
This intelligence report provides a comprehensive analysis of the Global Neuropathic Pain Management Market. This includes Investigation of past progress, ongoing market scenarios, and future ...
via Bing News